Amedisys, Inc. (NASDAQ:AMED) Shares Bought by MetLife Investment Management LLC

MetLife Investment Management LLC grew its stake in Amedisys, Inc. (NASDAQ:AMED) by 9.5% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 18,449 shares of the health services provider’s stock after buying an additional 1,593 shares during the quarter. MetLife Investment Management LLC owned 0.06% of Amedisys worth $1,675,000 as of its most recent SEC filing.

Other hedge funds have also recently modified their holdings of the company. Blue Trust Inc. boosted its position in Amedisys by 55.1% in the 4th quarter. Blue Trust Inc. now owns 349 shares of the health services provider’s stock worth $34,000 after purchasing an additional 124 shares in the last quarter. HBW Advisory Services LLC acquired a new position in shares of Amedisys in the 4th quarter valued at $38,000. Versant Capital Management Inc boosted its holdings in Amedisys by 68.5% during the fourth quarter. Versant Capital Management Inc now owns 450 shares of the health services provider’s stock worth $41,000 after buying an additional 183 shares in the last quarter. Vestcor Inc acquired a new stake in Amedisys during the fourth quarter valued at $73,000. Finally, Venturi Wealth Management LLC increased its holdings in Amedisys by 397.4% in the fourth quarter. Venturi Wealth Management LLC now owns 975 shares of the health services provider’s stock valued at $89,000 after buying an additional 779 shares in the last quarter. Hedge funds and other institutional investors own 94.36% of the company’s stock.

Analyst Ratings Changes

A number of research firms have recently commented on AMED. Stephens restated an “equal weight” rating and set a $101.00 target price on shares of Amedisys in a research report on Tuesday, March 4th. Royal Bank of Canada restated an “outperform” rating and issued a $100.00 price objective on shares of Amedisys in a research report on Wednesday, April 16th. Four equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $100.75.

Amedisys Stock Up 0.0 %

NASDAQ AMED opened at $94.72 on Wednesday. Amedisys, Inc. has a one year low of $82.15 and a one year high of $98.95. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.19 and a current ratio of 1.19. The business has a fifty day moving average price of $92.32 and a 200 day moving average price of $91.76. The company has a market cap of $3.11 billion, a P/E ratio of 37.59, a P/E/G ratio of 1.78 and a beta of 0.89.

Amedisys (NASDAQ:AMED) last posted its quarterly earnings results on Wednesday, April 23rd. The health services provider reported $1.25 earnings per share for the quarter, topping analysts’ consensus estimates of $1.13 by $0.12. The firm had revenue of $594.78 million for the quarter, compared to analyst estimates of $597.43 million. Amedisys had a net margin of 3.57% and a return on equity of 12.20%. Amedisys’s quarterly revenue was up 4.1% on a year-over-year basis. During the same period in the previous year, the business posted $1.03 earnings per share. Research analysts anticipate that Amedisys, Inc. will post 4.4 EPS for the current fiscal year.

Amedisys Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.